Antithrombin (Recombinant)

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.

Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The September 2009 monograph topics are dronedarone, prasugrel, ferumoxytol injection, canakinumab injection, and ibuprofen injection. The DUE is on dronedarone.

Get full access to this article

View all access options for this article.

References

ATryn [package insert]. Deerfield, IL: Ovation Pharmaceuticals, Inc; February 2009.

Thrombate III [package insert]. Research Triangle Park, NC: Talecris Biotherapeutics, Inc; August 2008.

Maclean

P.S.

, Tait

R.C.

Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs. 2007; 67(10): 1429–1440.

Patnaik

M.M.

, Moll

Inherited antithrombin deficiency: a review. Haemophilia. 2008; 14(6): 1229–1239.

Levy

J.H.

, Weisinger

, Ziomek

C.A.

, Echelard

Recombinant antithrombin: production and role in cardiovascular disorder. Semin Thromb Hemost. 2001; 27(4): 405–416.

Echelard

, Ziomek

C.A.

, Meade

H.M.

Production of recombinant therapeutic proteins in the milk of transgenic animals. BioPharm Int. 2006; 19(8): 36–45.

Ziomek

C.A.

, Kutzko

, Sherman

Viral and prion safety of recombinant human antithrombin [abstract]. Ann Hematol. 2003; 82(Suppl 1): S95.

Roemisch

, Gray

, Hoffmann

J.N.

, Wiedermann

C.J.

Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis. 2002; 13(8): 657–670.

Leitner

J.M.

, Firbas

, Mayr

F.B.

, Reiter

R.A.

, Steinlechner

, Jilma

Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clin Pharmacol Ther. 2006; 79(1): 23–34.

10.

Edmunds

, Van Patten

S.M.

, Pollock

Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood. 1998; 91(12): 4561–4571.

11.

, Mant

, Levy

J.H.

, Bailey

J.M.

Pharmacokinetics of recombinant transgenic antithrombin in volunteers. Anesth Analg. 2000; 90(3): 531–534.

12.

Jain

FDA briefing document. Blood Products Advisory Committee meeting: ATryn (antithrombin III [recombinant]), GTC Biopharmaceuticals Inc. http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009–4410B1–5.htm. Published January 9, 2009. Accessed March 2, 2009.

13.

Tiede

, Tait

R.C.

, Shaffer

D.W.

Antithrombin alfa in hereditary antithrombin deficient patients: a phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost. 2008; 99(3): 616–622.

14.

Tait

R.C.

, Frieling

J.T.M.

, Drenth

H.J.

, Bonfiglio

Management of AT activity levels with antithrombin alfa in hereditary AT deficient patients during surgery [abstract]. J Thromb Haemost. 2007; 5(Suppl 2): P-M-478.

15.

Frieling

J.T.M.

, Drenth

H.J.

, Bonfiglio

, Tait

R.C.

Pregnant hereditary antithrombin deficient women require a distinct dosing strategy for the management of AT activity levels with antithrombin alfa [abstract]. J Thromb Haemost. 2007; 5(Suppl 2): P-M-479.

16.

von Depka

, Shaffer

, Baudo

Safety and efficacy of prophylactic intravenous administration of recombinant human antithrombin (rhAT) to hereditary AT deficient patients in high-risk situations [abstract]. Blood. 2004; 104: abstract 4076.

17.

Tait

R.C.

, Frieling

J.T.M.

Antithrombin alfa in hereditary antithrombin deficient patients at high risk for thromboembolic complications [abstract]. Blood. 2008; 112: abstract 986.

18.

Konkle

B.A.

, Bauer

K.A.

, Weinstein

, Greist

, Holmes

H.E.

, Bonfiglio

Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion. 2003; 43(3): 390–394.

19.

Avidan

M.S.

, Levy

J.H.

, Scholz

A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology. 2005; 102(2): 276–284.

20.

Avidan

M.S.

, Levy

J.H.

, van Aken

Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005; 130(1): 107–113.

21.

Levy

J.H.

, Despotis

G.J.

, Szlam

, Olson

, Meeker

, Weisinger

Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesiology. 2002; 96(5): 1095–1102.

22.

Richards

S.M.

, Welch

, Noyst

Assessment of immunogenicity of recombinant human antithrombin human clinical studies [abstract]. Ann Hematol. 2003; 82(Suppl 1): S72.

23.

Frieling

, Ziomek

, Masiello

No immunogenicity found to antithrombin alfa in human clinical studies [abstract]. Blood. 2007; 110: abstract 3197.